Which has better valuation & earnings, CARL or LNSR?

Carlsmed has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 6.33 -$29.63M -$2.51 N/A LENSAR $58.44M 1.19 -$34.28M -$0.58 N/A

Is CARL or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.76% -60.74% -29.84% LENSAR 50.94% -183.19% 42.26%

Which has preferable earnings & valuation, OBIO or LNSR?

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 7.58 -$52.70M -$0.97 N/A LENSAR $58.44M 1.19 -$34.28M -$0.58 N/A

Is OBIO or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% LENSAR 50.94% -183.19% 42.26%

Which has better earnings & valuation, PROF or LNSR?

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 14.67 -$42.57M -$1.24 N/A LENSAR $58.44M 1.19 -$34.28M -$0.58 N/A

Is PROF or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -206.76% -78.88% -64.06% LENSAR 50.94% -183.19% 42.26%

LENSAR (LNSR) Competitors

$5.65 +0.02 (+0.36%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$5.60 -0.05 (-0.85%)

As of 04:30 AM Eastern

Compare

LNSR vs. CARL, TMCI, TLSI, OBIO, and PROF

Should you buy LENSAR stock or one of its competitors? MarketBeat compares LENSAR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENSAR include Carlsmed (CARL), Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.

How does LENSAR compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and LENSAR (NASDAQ:LNSR) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Carlsmed has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	6.33	-$29.63M	-$2.51	N/A
LENSAR	$58.44M	1.19	-$34.28M	-$0.58	N/A

40.2% of LENSAR shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Carlsmed had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Carlsmed and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.89 beat Carlsmed's score of 0.94 indicating that LENSAR is being referred to more favorably in the news media.

Company	Overall Sentiment
Carlsmed	Positive
LENSAR	Very Positive

LENSAR has a net margin of 50.94% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
LENSAR	50.94%	-183.19%	42.26%

Carlsmed presently has a consensus price target of $19.33, suggesting a potential upside of 64.43%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 76.99%. Given LENSAR's higher possible upside, analysts clearly believe LENSAR is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

LENSAR beats Carlsmed on 8 of the 15 factors compared between the two stocks.

How does LENSAR compare to Treace Medical Concepts?

LENSAR (NASDAQ:LNSR) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, LENSAR and LENSAR both had 1 articles in the media. LENSAR's average media sentiment score of 1.89 beat Treace Medical Concepts' score of 0.94 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Very Positive
Treace Medical Concepts	Positive

LENSAR has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

LENSAR has a net margin of 50.94% compared to Treace Medical Concepts' net margin of -29.44%. Treace Medical Concepts' return on equity of -67.04% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

LENSAR has higher earnings, but lower revenue than Treace Medical Concepts. LENSAR is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.19	-$34.28M	-$0.58	N/A
Treace Medical Concepts	$212.69M	1.36	-$59M	-$0.97	N/A

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LENSAR currently has a consensus target price of $10.00, indicating a potential upside of 76.99%. Treace Medical Concepts has a consensus target price of $4.77, indicating a potential upside of 6.95%. Given LENSAR's stronger consensus rating and higher possible upside, equities analysts plainly believe LENSAR is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Summary

LENSAR beats Treace Medical Concepts on 9 of the 15 factors compared between the two stocks.

How does LENSAR compare to TriSalus Life Sciences?

LENSAR (NASDAQ:LNSR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, TriSalus Life Sciences had 3 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for TriSalus Life Sciences and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.89 beat TriSalus Life Sciences' score of 0.47 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Very Positive
TriSalus Life Sciences	Neutral

LENSAR has a net margin of 50.94% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

40.2% of LENSAR shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LENSAR currently has a consensus price target of $10.00, suggesting a potential upside of 76.99%. TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 58.56%. Given LENSAR's stronger consensus rating and higher possible upside, equities analysts plainly believe LENSAR is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

LENSAR has higher revenue and earnings than TriSalus Life Sciences. LENSAR is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.19	-$34.28M	-$0.58	N/A
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A

Summary

LENSAR beats TriSalus Life Sciences on 11 of the 15 factors compared between the two stocks.

How does LENSAR compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
LENSAR	50.94%	-183.19%	42.26%

Orchestra BioMed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 65.8% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Orchestra BioMed had 2 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for Orchestra BioMed and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.89 beat Orchestra BioMed's score of 0.89 indicating that LENSAR is being referred to more favorably in the news media.

Company	Overall Sentiment
Orchestra BioMed	Positive
LENSAR	Very Positive

Orchestra BioMed presently has a consensus target price of $13.60, indicating a potential upside of 220.75%. LENSAR has a consensus target price of $10.00, indicating a potential upside of 76.99%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, research analysts plainly believe Orchestra BioMed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	7.58	-$52.70M	-$0.97	N/A
LENSAR	$58.44M	1.19	-$34.28M	-$0.58	N/A

Summary

Orchestra BioMed and LENSAR tied by winning 8 of the 16 factors compared between the two stocks.

How does LENSAR compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
LENSAR	50.94%	-183.19%	42.26%

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A
LENSAR	$58.44M	1.19	-$34.28M	-$0.58	N/A

Profound Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Profound Medical had 2 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for Profound Medical and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.89 beat Profound Medical's score of 0.88 indicating that LENSAR is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Positive
LENSAR	Very Positive

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profound Medical currently has a consensus target price of $12.00, indicating a potential upside of 84.62%. LENSAR has a consensus target price of $10.00, indicating a potential upside of 76.99%. Given Profound Medical's higher possible upside, analysts clearly believe Profound Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

LENSAR beats Profound Medical on 10 of the 16 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNSR vs. The Competition

Export

Metric	LENSAR	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$69.38M	$7.36B	$6.83B	$12.17B
Dividend Yield	N/A	1.24%	2.66%	6.11%
P/E Ratio	-9.74	51.24	25.91	24.17
Price / Sales	1.19	48.76	548.81	101.11
Price / Cash	N/A	26.99	29.09	36.93
Price / Book	-2.59	7.53	10.82	6.38
Net Income	-$34.28M	$159.19M	$3.58B	$337.00M
7 Day Performance	-0.18%	2.61%	1.90%	-0.23%
1 Month Performance	-2.59%	-2.37%	-0.26%	-1.40%
1 Year Performance	-55.72%	5.96%	34.40%	27.76%

LENSAR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNSR LENSAR	1.8297 of 5 stars	$5.65 +0.4%	$10.00 +77.0%	-55.7%	$69.38M	$58.44M	N/A	110	Positive News Gap Up High Trading Volume
CARL Carlsmed	2.6532 of 5 stars	$10.69 +8.6%	$19.33 +80.9%	N/A	$267.50M	$50.51M	N/A	100	Analyst Upgrade
TMCI Treace Medical Concepts	1.801 of 5 stars	$4.49 +12.0%	$4.77 +6.2%	-22.4%	$260.14M	$207.32M	N/A	250
TLSI TriSalus Life Sciences	3.639 of 5 stars	$4.03 -4.0%	$7.50 +86.1%	-11.1%	$257.95M	$45.15M	N/A	106
OBIO Orchestra BioMed	3.9032 of 5 stars	$4.04 -1.0%	$13.60 +236.6%	+52.5%	$244.31M	$32.72M	N/A	4	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENSAR (LNSR) Competitors

LNSR vs. CARL, TMCI, TLSI, OBIO, and PROF

How does LENSAR compare to Carlsmed?

Summary

How does LENSAR compare to Treace Medical Concepts?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Summary

How does LENSAR compare to Orchestra BioMed?

Summary

How does LENSAR compare to Profound Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENSAR (LNSR) Competitors

LNSR vs. CARL, TMCI, TLSI, OBIO, and PROF

How does LENSAR compare to Carlsmed?

Which has better valuation & earnings, CARL or LNSR?

Do institutionals and insiders hold more shares of CARL or LNSR?

Does the media refer more to CARL or LNSR?

Is CARL or LNSR more profitable?

Do analysts rate CARL or LNSR?

Summary

How does LENSAR compare to Treace Medical Concepts?

Does the media prefer LNSR or TMCI?

Which has more volatility and risk, LNSR or TMCI?

Is LNSR or TMCI more profitable?

Which has stronger earnings & valuation, LNSR or TMCI?

Do institutionals and insiders believe in LNSR or TMCI?

Do analysts recommend LNSR or TMCI?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Which has more volatility and risk, LNSR or TLSI?

Does the media refer more to LNSR or TLSI?

Is LNSR or TLSI more profitable?

Do insiders and institutionals believe in LNSR or TLSI?

Do analysts prefer LNSR or TLSI?

Which has stronger valuation and earnings, LNSR or TLSI?

Summary

How does LENSAR compare to Orchestra BioMed?

Is OBIO or LNSR more profitable?

Which has more risk & volatility, OBIO or LNSR?

Do insiders & institutionals believe in OBIO or LNSR?

Does the media favor OBIO or LNSR?

Do analysts prefer OBIO or LNSR?

Which has preferable earnings & valuation, OBIO or LNSR?

Summary

How does LENSAR compare to Profound Medical?

Is PROF or LNSR more profitable?

Which has better earnings & valuation, PROF or LNSR?

Which has more volatility & risk, PROF or LNSR?

Does the media prefer PROF or LNSR?

Do institutionals & insiders believe in PROF or LNSR?

Do analysts recommend PROF or LNSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools